Pomalidomide manufacturer
Pomalidomide is indicated for patients who have relapsed or become refractory to previous treatments, including other IMiDs like lenalidomide and proteasome inhibitors such as bortezomib. Its approval has provided oncologists with a valuable tool in managing challenging cases of multiple myeloma, where traditional therapies have been exhausted or ineffective.